Drug Trial Radar · NCT02934529
Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab
Last checked: Nov 19, 2026Latest source record: Apr 16, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
673
Actual
Start
Mar 2015
Primary completion
Jan 30, 2025
Study completion Jan 30, 2025
Sponsor
- Lead sponsor
- Ludwig-Maximilians - University of MunichAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 17, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The FIRE-4 study aims to define a treatment concept for patients with RAS wild-type tumours, optimised with regard to overall survival. The first-line treatment will be conducted with FOLFIRI plus cetuximab, which resulted in a significantly prolonged overall survival versus bevacizumab in the FIRE-3 study. Following initial progression (PD1) it is recommended that the treatment be continued with FOLFOX plus bevacizumab, as this concept led to significantly prolonged survival in the E3200 study. Owing to the encouraging results of the Santini study , a cetuximab rechallenge in combination with irinotecan-based chemotherapy is to be performed as part of the third-line treatment in patients who showed a response defined according to RECIST 1.1 during the first-line treatment (tumour diameter \< -30%) or presented with stable tumour disease for at least 6 months (tumour diameter +20 to -30%). The concept of the ideal sequence has not yet been studied to date in a clinical trial.
Conditions
- Metastatic Colorectal Cancer
Interventions
IrinotecanDrug
Irinotecan 180 mg/m² iv, 30 - 90 min., day 1, q d15
Folinic AcidDrug
Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1, q d15
5-FUDrug
5-FU 400 mg/m² bolus day 1, q d15
5-FUDrug
5-FU 2400 mg/m² iv over 46 h day 1-2, q d15
CetuximabDrug
cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) day 1 + 8
BevacizumabDrug
Bevacizumab 7.5 mg/kg BW iv over 30 to 90 minutes: day 1
CapecitabineDrug
Capecitabine 1250 mg/m2 2 x day p.o. day 1-14, q d15
regorafenibDrug
160 mg per day (day 1-21) (repeated on day 28)
Irinotecan 125mgDrug
Irinotecan 125 mg/m² iv, 60 - 90 min. weekly (D1, D8, D15, D22)
Cetuximab wklyDrug
Cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) weekly (D1, D8, D15, D22, D29, D36)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: up to 55 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Klinikum der Universitaet Muenchen - Campus Grosshadern
Munich, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.